Riboscience LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.riboscience.com
RSV Treatment Landscape Expands with New Vaccines and Clinical Trials in 2024-2025
• Moderna's mRESVIA vaccine received MHRA approval in February 2025 for adults aged 60 and older, joining GSK's Arexvy and Pfizer's Abrysvo in the expanding RSV vaccine market.
• The FDA has mandated new safety warnings for RSV vaccines regarding Guillain-Barré Syndrome risk, highlighting ongoing safety monitoring efforts in early 2025.
• Multiple pharmaceutical companies including Sanofi, GSK, and Pfizer are conducting advanced clinical trials in 2024, focusing on various patient populations and novel therapeutic approaches.
RSV Therapeutic Pipeline Shows Promise with Novel Therapies and Clinical Advancements
• Over 50 companies are actively developing more than 50 therapeutic options for Respiratory Syncytial Virus (RSV) treatment, indicating a robust pipeline.
• GSK's Arexvy vaccine demonstrated encouraging Phase III results, preventing lower respiratory tract disease (LRTD) in older adults across three RSV seasons.
• Merck's clesrovimab showed positive topline results in a Phase IIb/III trial as a preventive treatment for RSV in infants, highlighting potential for vulnerable populations.
© Copyright 2025. All Rights Reserved by MedPath